SCHEMBL83033

SCHEMBL83033

CCCCCCC1CC(=O)NC1=O

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.54
L3MBTL1 Q9Y468 2/20 0.54
CYP19A1 P11511 5/20 0.46
NPC1 O15118 1/20 0.44
KMT2A Q03164 2/20 0.40
POLB P06746 2/20 0.40
CYP1A2 P05177 3/20 0.40
KDM4E B2RXH2 2/20 0.39
MEN1 O00255 1/20 0.39
MAPT P10636 1/20 0.39
PKM P14618 1/20 0.39
HPGD P15428 1/20 0.39
GLA P06280 1/20 0.39
HLCS P50747 1/20 0.38
MAP3K14 Q99558 1/20 0.38
LMNA P02545 1/20 0.37
PRKCA P17252 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL735231 1.00 ALDH1A1 (0.54) ALDH1A1L3MBTL1CYP19A1NPC1KMT2A
SCHEMBL8697031 1.00 ALDH1A1 (0.54) ALDH1A1L3MBTL1CYP19A1NPC1KMT2A
SCHEMBL734158 1.00 ALDH1A1 (0.54) ALDH1A1L3MBTL1CYP19A1NPC1KMT2A
SCHEMBL18626078 1.00 ALDH1A1 (0.54) ALDH1A1L3MBTL1CYP19A1NPC1KMT2A
SCHEMBL3372427 1.00 ALDH1A1 (0.54) ALDH1A1L3MBTL1CYP19A1NPC1KMT2A
SCHEMBL734754 1.00 ALDH1A1 (0.54) ALDH1A1L3MBTL1CYP19A1NPC1KMT2A
SCHEMBL11727127 1.00 ALDH1A1 (0.54) ALDH1A1L3MBTL1CYP19A1NPC1KMT2A
SCHEMBL6536968 1.00 ALDH1A1 (0.54) ALDH1A1L3MBTL1CYP19A1NPC1KMT2A
SCHEMBL5617175 1.00 ALDH1A1 (0.54) ALDH1A1L3MBTL1CYP19A1NPC1KMT2A
SCHEMBL7643509 1.00 ALDH1A1 (0.54) ALDH1A1L3MBTL1CYP19A1NPC1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4607319-B2 2011-01-05 JP claimed
JP-2002512190-A 2002-04-23 JP claimed
EP-1079832-A1 USE OF VITAMIN PP COMPOUNDS Klinge Pharma GmbH (DE) 2001-03-07 EP claimed
EP-1042315-A1 CYCLIC IMIDE-SUBSTITUTED PYRIDYLALKANE, ALKENE, AND ALKINE CARBOXAMIDES USEFUL AS CYTOSTATIC AND IMMUNOSUPPRESSIVE AGENTS Klinge Pharma GmbH (DE) 2000-10-11 EP claimed
WO-1999053920-A1 USE OF VITAMIN PP COMPOUNDS KLINGE PHARMA GMBH (DE) 1999-10-28 WO claimed
WO-1999031087-A1 CYCLIC IMIDE-SUBSTITUTED PYRIDYLALKANE, ALKENE AND ALKINE CARBOXAMIDES USEFUL AS CYTOSTATIC AND IMMUNOSUPPRESSIVE AGENTS KLINGE PHARMA GMBH (DE) 1999-06-24 WO claimed
WO-2023288226-A2 POLYMER ENGINEERED FORMS OF INTERFERON-GAMMA AND METHODS OF USE NEKTAR THERAPEUTICS (US) 2023-01-19 WO disclosed
US-20180134717-A1 PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF SPIROGEN LIMITED (GB) 2018-05-17 US disclosed
US-9649390-B2 Pyrrolobenzodiazepines and conjugates thereof MEDIMMUNE LIMITED (GB) 2017-05-16 US disclosed
CN-104031140-B Truncated analogues of glucose-dependent insulinotropic polypeptide 益普生制药股份有限公司 2017-04-12 CN disclosed
US-9567340-B2 Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases MEDIMMUNE LIMITED (GB) 2017-02-14 US disclosed
EP-2915538-A2 Truncated analogues of glucose-dependent insulinotropic polypeptide IPSEN PHARMA S.A.S. (FR) 2015-09-09 EP disclosed
EP-2320923-B1 TRUNCATED ANALOGUES OF GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE IPSEN PHARMA SAS (FR) 2014-12-24 EP disclosed
CN-1102601-C Unsaturated copolymer based on olefin and production and use thereof MITSUI PETROCHEMICAL IND (JP) 2003-03-05 CN disclosed
CN-1344283-A Ethylene copolymer rubber, process for producing the same, and use thereof MITSUI CHEMICALS INC (JP) 2002-04-10 CN disclosed
EP-1079832-A1 USE OF VITAMIN PP COMPOUNDS Klinge Pharma GmbH (DE) 2001-03-07 EP disclosed
EP-1042315-A1 CYCLIC IMIDE-SUBSTITUTED PYRIDYLALKANE, ALKENE, AND ALKINE CARBOXAMIDES USEFUL AS CYTOSTATIC AND IMMUNOSUPPRESSIVE AGENTS Klinge Pharma GmbH (DE) 2000-10-11 EP disclosed
WO-1999053920-A1 USE OF VITAMIN PP COMPOUNDS KLINGE PHARMA GMBH (DE) 1999-10-28 WO disclosed
WO-1999031087-A1 CYCLIC IMIDE-SUBSTITUTED PYRIDYLALKANE, ALKENE AND ALKINE CARBOXAMIDES USEFUL AS CYTOSTATIC AND IMMUNOSUPPRESSIVE AGENTS KLINGE PHARMA GMBH (DE) 1999-06-24 WO disclosed
CN-1166501-A Unsaturated copolymer based on olefin and production and use thereof MITSUI PETROCHEMICAL IND (JP) 1997-12-03 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180134717-A1 PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF HDAC10, PBDC1, PDCD10 ALDH1A1 1192/4885L3MBTL1 243/4885CYP19A1 2034/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.